AA
MRSN

AlphaCentric Advisors’s Mersana Therapeutics MRSN Stock Holding History

AlphaCentric Advisors’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,620
Closed -$618K – 255
2021
Q3 		$618K Buy
2,620
+800
+44% +$234K 0.16% 57
2021
Q2 		$618K Buy
1,820
+600
+49% +$227K 0.17% 52
2021
Q1 		$493K Buy
1,220
+1,036
+563% +$503K 0.17% 47
2020
Q4 		$122K Buy
184
+70
+61% +$38.9K 0.05% 102
2020
Q3 		$53K Buy
+114
New +$57.6K 0.03% 100

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

AlphaCentric Advisors's MRSN Position: Q4 2021 in Review

AlphaCentric Advisors sold out of Mersana Therapeutics (MRSN) in Q4 2021, closing a stake of 2,620 shares — an estimated $618K sold.

AlphaCentric Advisors first reported a position in MRSN in Q3 2020 and held it in 5 quarters. The position peaked at $618K in Q3 2021. 122 funds tracked by Wall St. Rank hold MRSN as of Q4 2021.

  • AlphaCentric Advisors reported no remaining Mersana Therapeutics position as of Q4 2021 after selling out during the quarter.
  • AlphaCentric Advisors sold 2,620 Mersana Therapeutics shares in Q4 2021, an estimated $618K.
  • AlphaCentric Advisors first reported a position in Mersana Therapeutics in Q3 2020 and held it in 5 quarters.
  • AlphaCentric Advisors's Mersana Therapeutics position peaked at $618K in Q3 2021.
  • 122 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.